Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
Arribas, Jose R, Dr, Pialoux, Gilles, Prof, Gathe, Joseph, MD, Di Perri, Giovanni, Prof, Reynes, Jacques, Prof, Tebas, Pablo, MD, Nguyen, Thai, MD, Ebrahimi, Ramin, MS, White, Kirsten, PhD, Piontkowsky, David, MD
Published in The Lancet infectious diseases (01.07.2014)
Published in The Lancet infectious diseases (01.07.2014)
Get full text
Journal Article